Current treatments for Parkinson’s disease are symptomatic and only address a subset of symptoms such as motor impairment, dementia or psychosis. Symptomatic therapies do not target the underlying cause of the disease and lose effectiveness, often leading to debilitating side effects as the disease progresses. There are currently no treatments available that target the underlying cause of the disease and can slow or stop the progression.
Prasinezumab is a first-in-class therapeutic with the goal of reducing clinical decline in Parkinson’s disease. Prasinezumab targets α-synuclein and is designed to block the cell-to-cell transmission of the aggregated pathogenic forms of α-synuclein that are the cause of Parkinson’s disease, thereby slowing clinical decline.
Prasinezumab is currently in a Phase 2b PADOVA study and an ongoing long term extension of Phase 2 PASADENA study. Both studies are being conducted by our partners at Roche.